Iovance Biotherapeutics, Inc.
IOVANext catalyst
E7 TCR-T cells
Cervical Cancer
Get an email about IOVA's next catalysts
Track Iovance Biotherapeutics (IOVA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
4 upcoming, 0 past
IOVA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.09 | FQ end Sep/2026 | Call: tbd
E7 TCR-T cells Phase 2 Est. Readout
Estimated primary completion for E7 TCR-T cells trial (NCT05686226) in Cervical Cancer. Topline data typically follows completion by weeks to months.
SourceAldesleukin Phase 2 Est. Readout
Estimated primary completion for Aldesleukin trial (NCT03449108) in Bone Sarcoma. Topline data typically follows completion by weeks to months.
SourceIOV-4001 Phase 2 Est. Readout
Estimated primary completion for IOV-4001 trial (NCT05361174) in Unresectable Melanoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
WebsiteLifileucel plus Pembrolizumab
Metastatic Melanoma
IOV-3001
Unresectable Melanoma
IOV-2001
Chronic Lymphocytic Leukemia
LN-145-S1
Squamous Cell Carcinoma of the Head and Neck
Lifileucel
Endometrial Cancer
IOV-4001
Unresectable Melanoma
Autologous Tumor Infiltrating Lymphocytes LN-145
Bone Sarcoma
E7 TCR-T cells
Cervical Cancer
Aldesleukin
HPV-Associated Cervical Carcinoma
Tumor infiltrating lymphocytes (TIL) LN-145
Metastatic Triple Negative Breast Cancer
LN-145
Metastatic Non Small Cell Lung Cancer
Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Bone Sarcoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma | - | - |
IOV-3001 | Phase 2 | Unresectable Melanoma | - | - |
IOV-2001 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
LN-145-S1 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Lifileucel | Phase 2 | Endometrial Cancer | - | - |
IOV-4001 | Phase 2 | Unresectable Melanoma | - | - |
Autologous Tumor Infiltrating Lymphocytes LN-145 | Phase 2 | Bone Sarcoma | - | - |
E7 TCR-T cells | Phase 2 | Cervical Cancer | - | - |
Aldesleukin | Phase 2 | HPV-Associated Cervical Carcinoma | - | - |
Tumor infiltrating lymphocytes (TIL) LN-145 | Phase 2 | Metastatic Triple Negative Breast Cancer | - | - |
LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer | - | - |
Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | Phase 2 | Bone Sarcoma | - | - |
Unresectable Melanoma
2 drugs in this indication
Chronic Lymphocytic Leukemia
1 drug in this indication
Metastatic Melanoma
1 drug in this indication
Squamous Cell Carcinoma of the Head and Neck
1 drug in this indication
Endometrial Cancer
1 drug in this indication
Metastatic Non Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Iovance Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Iovance Biotherapeutics, Inc.'s (IOVA) pipeline across Phase 3, Phase 2. Its lead program is Lifileucel plus Pembrolizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Iovance Biotherapeutics, Inc.'s next FDA catalyst?→
Iovance Biotherapeutics, Inc.'s (IOVA) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IOVA biotech catalysts?→
Add IOVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Iovance Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.